Writing AI Model Cards Hospitals Will Actually Approve

The fastest way to get an AI project blocked in a hospital is to hand procurement a glossy slide deck and call it governance.

I have watched strong models die in review because the team could not answer basic questions in one place: What exactly does it do? Who was it trained on? Where does it fail? What happens when a clinician uses it wrong? A model card solves that problem, but only if you write it for the people who actually approve deployments.

That means two audiences at once: procurement, which wants contractual clarity and risk control, and clinical governance, which wants evidence that the model is safe, bounded, and suitable for the intended workflow. If your model card reads like research marketing, it fails both.

Why AI model cards get rejected

The mistake I see most often is simple: teams write model cards for data scientists, not for hospital reviewers. They bury the key facts in technical language, or they leave out the ugly parts because they think caveats make the model look weak. The opposite is true.

One of our AST pods supported a respiratory workflow deployment where the model performed well overall, but the first governance review stalled because the card said “broad patient population” without spelling out the excluded groups. The board did not want optimism. They wanted boundaries. We rewrote the card with explicit inclusion and exclusion criteria, and the approval moved.

A good model card is not a brochure. It is a controlled artifact that answers the questions a hospital is already asking.

What to include in an AI model card for hospitals

Keep it short enough to be read, but complete enough to be trusted. I use the same core sections every time because hospital reviewers need the same evidence every time.

Those five sections are the backbone. Everything else is supporting detail.

Write the intended use like a contract

This section should be brutally specific. I want to know where the model sits in the workflow, who sees the output, and what it is not allowed to do.

Bad version: “This model supports clinical decision making for respiratory patients.”

Better version: “This model flags patients at elevated risk of deterioration for nurse review in the inpatient respiratory monitoring workflow. It does not diagnose, prescribe, or replace clinician judgment. It is not used for discharge decisions.”

That level of precision matters because hospital governance boards are thinking like risk managers. Procurement is thinking like risk managers too. If your intended use is fuzzy, your liability story is fuzzy.

Training data: show the full lineage

Hospitals want to know where the model came from, not just what it can do. I always include:

• Data source and owner
• Collection dates
• Number of records and patients
• Site mix or geography
• Labeling method and reviewer type
• Exclusions and missingness

This is where teams often get nervous, especially if the data is proprietary or collected across multiple systems. I do not advise hand-waving. I advise clarity. If the model was trained on data from three health systems and one had incomplete coding for a year, say so. If certain age groups were underrepresented, say so. Governance teams respect candor because it lets them assess risk.

Validation should look like clinical evidence, not benchmark theater

This is where a lot of AI teams lose trust. They present impressive technical metrics and ignore the actual care setting. Hospital reviewers want to know whether the model worked on held-out data, what population it was tested on, and whether the test conditions resembled deployment.

Include the validation design, the baseline, the chosen threshold, and the operational meaning of the metric. If sensitivity went up but false positives doubled, say that. If calibration was excellent in one site and weaker in another, say that too.

One thing I disagree with strongly: too many teams hide behind aggregate performance. In one AST implementation, the overall validation looked acceptable until we split the results by facility type. The model was materially weaker in smaller sites with different documentation patterns. That detail changed the rollout plan completely. It should have been in the first version of the card.

Bias assessment is not a checkbox

If your model card says “bias assessed” and stops there, expect pushback. Clinical governance teams now expect a subgroup analysis, even if it is imperfect. At minimum, show performance by age, sex, race and ethnicity where legally and ethically appropriate, plus any clinically relevant groups for the use case.

Then go one step further: explain what you did when disparity appeared. Did you tune the threshold? Retrain? Restrict use? Add human review? A good model card does not pretend bias does not exist. It shows that you found it, measured it, and made a decision.

In our work across AST’s integrated engineering pods, the model cards that move fastest are the ones that treat fairness as an engineering outcome, not a compliance slogan. That change in tone matters in review.

Known failure modes belong upfront

This section earns trust faster than any other. I want concrete failure modes, not vague disclaimer language.

• Performance drops when notes are sparse
• Output is less reliable for transferred patients
• Thresholds behave differently after EHR template changes
• False positives rise during system downtime or delayed lab feeds
• Human override patterns are inconsistent in night shifts

That last point is important. Hospitals do not deploy models into a clean lab environment. They deploy into interrupted workflows, templated notes, odd staffing mixes, and inconsistent data feeds. If your model card ignores operational failure, it is incomplete.

What procurement is really looking for

Procurement does not want a thesis. It wants enough documentation to make the vendor review defensible.

So include:

• Version number and release date
• Change history from prior version
• Dependencies and integration requirements
• Security and access controls at a high level
• Support and escalation path
• Intended deployment environment

When I work with hospital teams, I see the same pattern: clinical governance asks whether the model is safe, and procurement asks whether the vendor can support what was promised. A strong model card helps both because it ties the product to a stable versioned artifact.

A practical structure that works

If I were building this from scratch, I would use this order:

1. Model name, version, owner, and date
2. Intended use and out-of-scope use
3. Training data summary
4. Validation summary
5. Bias and subgroup analysis
6. Known limitations and failure modes
7. Monitoring plan after deployment
8. Change log and approval contacts

That structure mirrors how hospitals think during review. It also makes the document usable after approval, which is where a lot of model cards fail. A card that cannot support post-deployment monitoring is not finished.

AST perspective: write it like it will be audited

At AST, we build for approval and for the day after approval. In one deployment for a respiratory care client, the model card had to be revised three times before governance was satisfied, not because the model was weak, but because the documentation was too vague to support operational ownership. In another, the first version omitted threshold rationale, and procurement flagged it because the contract language and the clinical language did not match. That is not a paperwork problem. That is a delivery problem.

The model card should be written by people who understand the product, the workflow, and the audit trail. If you do not have that alignment, you will keep rewriting it after every review cycle.

My rule is simple: if the model card does not let a reviewer explain the system to a skeptical clinician in five minutes, it is not ready.